New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 8 #6/7 October 2005


MEETING COVERAGE

PHASE I MONOTHERAPY CLINICAL TRIALS IN ONCOLOGY
FROM THE 2005 MEETINGS OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) AND THE AMERICAN ASSOCIATION OF CLINICAL ONCOLOGY (ASCO)

PHASE I MONOTHERAPY CLINICAL TRIALS
  • Patient Selection
  • Trial Initiation
  • Dosing and Treatment Schedules
    • Microdosing/phase 0 clinical trials
    • Personalized dosing
  • Informed Consent and Patient Recruitment
  • Phase I Clinical Trial Reporting
  • Decision to Advance Development of Agents Based on Phase I Clinical Trials
  • Benefits of Phase I Monotherapy in Oncology

NOVEL ANTICANCER AGENTS/FORMULATIONS IN PHASE I MONOTHERAPY TRIALS

  • Cytotoxic Agents, Targeted Cytotoxics, Apoptosis Inducters, and Immunoconjugates
    • AQ4N
    • C-1311
    • CHR-2797
    • CMC-544
    • CYC682
    • DOXO-EMCH
    • DTS-201
    • FFC11
    • FFC14A
    • KOS-1584
    • IPdR
    • MPC-2130
    • MPC-6827
    • MST-997
    • SB-743921
    • SR271425
    • XR5944
  • Hormone Modulators
    • CC-8490
  • Histone Deacetylase Inhibitors (HDAC)
    • CRA-023781
    • LBH589
    • MGCD0103
  • Regulatory/Targeted Agents, Cell-Cycle Modulators, Angiogenesis Inhibitors, and Vascular Targeting Agents (VTA)
    • AEE788
    • AS1411
    • ATN-224
    • AVE8062A
    • AZD0530
    • BAY 57-9352
    • BMS-599626
    • CTCE-9908
    • CX-3543
    • E7820
    • GRN163L
    • HGS-ETR2
    • KRN951
    • LErafAON-ETU
    • ON01910.Na
    • OXi4503
    • RAV12
    • SNS-595
    • SU014813
    • ZK-304709
  • Immunotherapy/Vaccines
    • GI-4000
    • IGN311
    • Interleukin-21 (IL-21)
    • KW-2871
    • Phosphostim
    • PSMA-based vaccine
    • RNA-loaded autologous dendritic cell (DC) vaccine
    • VX-001


LIST OF EXHIBITS

Exhibit 1 - Phase I Clinical Trial Terminology

Exhibit 2 - Overall Responses in Phase I Clinical Trials

Exhibit 3 - Responses in Monotherapy Phase I Clinical Trials

Exhibit 4 - Anticancer Agents in Phase I Monotherapy Clinical Trials with Recently Reported Preclinical or Clinical Findings

Exhibit 5 - Responses in Phase I Clinical Trials Involving Regulatory/Antiangiogenesis Agents

Exhibit 6 - Molecular Targets of Drugs in Phase I Clinical Trials

Exhibit 7 - Responses in Phase I Clinical Trials Involving Immunomodulators/Vaccines


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887